AN2 Therapeutics Inc (NASDAQ:ANTX) currently has a daily average trading volume of 377.17K but it saw 2213665 shares traded in last market. With a market cap of 31.32M USD, the company’s current market price of $1.05 came falling about -3.67 while comparing to the previous closing price of $1.09. In past 52 weeks, the stock remained buoying in the range of price level as high as $22.22 and as low as $0.87. In the recent trading on the day, stock has struck highest price mark of $1.0001 while lowest mark touched by it was $1.08.
Taking a look at 20-day trading activity of AN2 Therapeutics Inc (ANTX) gives us an average price of $2.3195, while its current price level is -95.27% below from 52-week high level whereas it is 20.69% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $2.2834 while that of 200 days or SMA-200 reads an average of $8.3272. A closer look into the stock’s movement over the week reveals that its volatility is standing at 24.06% during that period while stretching the period over a month that decreases to 11.26%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 22.20 which implies that the stock is in oversold territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Leerink Partners which downgraded the stock as “Market Perform” in its note to investors issued on August 09, 2024, recommending a price target of between $5 and $1 for it. Leerink Partners issued its recommendations for the stock as it upgraded the price target for the stock is $5.
Over the week, ANTX’s stock price is moving -57.49% down while it is -61.40% when we observe its performance for the past one month. Year-to-date it is -94.88% down and over the past year, the stock is showing a downside performance of -87.56%.
The latest quarterly earnings report issued by the company reported quarterly earnings per share (EPS) of -0.65 beaten by the consensus estimate of -0.63 for the same.
Currently, AN2 Therapeutics Inc’s total number of outstanding shares is 29.74M with 25.37% of that held by the insiders while 84.11% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -65.74% and return on equity (ROE) at -69.48%. Stock’s beta reads 0.06. Stock has a price to book (P/B) ratio of 0.32. Its return on asset (ROA) is -62.35% on average.
